文献速递膀胱癌与上尿路尿路上皮癌

美国临床实践中卡介苗治疗强度增加与非肌层浸润性膀胱癌老年患者结局改善相关

Increased Bacillus Calmette-Guérin Treatment Intensity Associated With Improved Outcomes in Elderly Patients With Non-Muscle-invasive Bladder Cancer in United States Clinical Practice.
PubMed 文献 · Urology · 2020-07-24

该回顾性分析基于美国SEER-Medicare数据库,纳入2000至2012年诊断的39,532例≥66岁0-1期尿路上皮膀胱癌患者,评估BCG治疗模式及结局。结果显示41.0%接受BCG,仅28.4%为充分治疗(≥5次诱导+≥2次维持);在12个月界标分析中,充分BCG与中高危患者复发及癌症特异和全因死亡风险降低相关,但半数中高危患者未接受BCG。

要点

  • 中高危非肌层浸润性膀胱癌老年患者中,仅少数接受充分BCG治疗。
  • 充分BCG(≥5次诱导+≥2次维持)与中高危患者复发和死亡风险降低相关。
  • 半数中高危患者未接受BCG,实践模式可能与指南推荐不一致。

核心结论

  • 在中高危非肌层浸润性膀胱癌老年患者中,充分BCG治疗使用率低于预期,尽管其与结局改善相关,提示实践模式可能不符合管理推荐。

研究设计与样本

  • 回顾性分析美国SEER-Medicare数据库2000至2012年诊断的≥66岁0-1期尿路上皮膀胱癌患者,共39,532例符合标准。

主要发现

  • 39,532例患者中16,225例(41.0%)接受BCG,其中4,602例(28.4%;总体11.6%)接受充分治疗。
  • 充分治疗患者比不充分治疗患者略年轻且更健康。
  • 半数中危和高危NMIBC患者未接受BCG,少数接受充分治疗。
  • 在12个月界标分析中,充分BCG治疗与中危和高危疾病患者复发、癌症特异死亡和全因死亡风险降低相关。

关键数值与推荐

  • 充分BCG定义为≥5次诱导灌注和≥2次维持灌注。
  • 按国家综合癌症网络(NCCN)风险组分层。

临床怎么用

  • 应关注中高危NMIBC老年患者BCG治疗不足的问题,并促进充分BCG治疗的实施以改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize Bacillus Calmette-Guérin (BCG) treatment patterns and associated outcomes in a large cohort of patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: Our retrospective analysis of patients aged ≥66 years with stage 0-1 urothelial bladder carcinoma diagnosed between 2000 and 2012 in the United States Surveillance, Epidemiology, and End Results-Medicare database estimated proxies for recurrence and secondary events and both all-cause and bladder cancer-specific mortality. Proportional hazards models were used in conditional landmark analyses to compare adequate (≥5 induction instillations and ≥2 maintenance instillations) and inadequate BCG, stratified by National Comprehensive Cancer Network risk group. RESULTS: Of 39,532 patients who met the selection criteria, 16,225 (41.0%) received BCG; of them, 4602 (28.4%; 11.6% overall) received adequate treatment. Adequately treated patients were slightly younger and healthier than inadequately treated patients. Half of patients with intermediate- and high-risk NMIBC did not receive BCG; few received adequate treatment. At the 12-month landmark, adequate BCG treatment was associated with decreased risks of recurrence and of cancer-specific and all-cause mortality in patients with intermediate- and high-risk disease. CONCLUSION: We observed lower than expected use of adequate BCG treatment in patients with intermediate- to high-risk NMIBC despite evidence of improved outcomes, which suggested that practice patterns may not be in line with management recommendations in this population.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Richards KA, Lin SW, Chuo CY, et al. Increased Bacillus Calmette-Guérin Treatment Intensity Associated With Improved Outcomes in Elderly Patients With Non-Muscle-invasive Bladder Cancer in United States Clinical Practice. Urology. 2020. PMID: 32717243. doi:10.1016/j.urology.2020.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。